Your Messages Inbox
Your Article Summary
See Latest Articles(Click the title below to leave the MDLinx Network and go to the Journal's Website)
Core portfolio of products delivers 20% sales growth
2009 guidance framework reaffirmed
Shire, 08/06/09
"In the second quarter we delivered strong core product sales, excluding ADDERALL XR, of $491 million, representing growth of 20% compared to the same quarter last year. The strategic steps we have taken over the last few years are now delivering clear commercial benefits, as we enter a new phase of Shire's development.
Today in Financial Reports...keeping you current
Receive free subspecialty "5-minute updates" via email
Report: Acquisition Activity Down
HealthDataManagement, 12/08/09
Genzyme Provides Update on Cerezyme Supply and 2009 Financial Information
Genzyme, 12/07/09
Medtronic Board Approves Third Quarter Cash Dividend for Fiscal Year 2010
Medtronic, 12/04/09
Article Search
Sponsor